caus
agent
sever
acut
respiratori
syndrom
sar
identifi
novel
coronaviru
sarscov
develop
rapid
screen
assay
essenti
antivir
drug
discoveri
use
cell
line
express
sarscov
subgenom
replicon
develop
highthroughput
assay
use
screen
small
molecul
compound
inhibitor
sarscov
replic
absenc
live
viru
assay
system
involv
minim
manipul
assay
setup
facilit
autom
readout
minim
risk
associ
hazard
virus
base
assay
system
screen
small
molecul
compound
identifi
compound
antisarscov
activ
demonstr
compound
inhibit
sarscov
replicationdepend
gfp
express
replicon
cell
reduc
sarscov
viral
protein
accumul
viral
rna
copi
number
replicon
cell
sarscov
plaqu
reduct
assay
compound
confirm
antivir
activ
target
one
hit
compound
valid
gener
resist
replicon
cell
identif
mutat
confer
resist
phenotyp
compound
valuabl
develop
antisar
therapeut
drug
well
research
tool
studi
mechan
sarscov
replic
sever
acut
respiratori
distress
syndrom
sar
emerg
begin
rapidli
spread
throughout
world
ksiazek
et
al
peiri
et
al
zhong
et
al
although
diseas
disappear
june
reemerg
exclud
develop
vaccin
sarscov
may
take
year
therefor
avail
effect
antivir
drug
sarscov
may
crucial
control
futur
sar
outbreak
sever
acut
respiratori
syndrom
sever
febril
lower
respiratori
ill
caus
newli
identifi
coronaviru
sar
coronaviru
sarscov
ksiazek
et
al
peiri
et
al
sarscov
genom
encompass
nucleotid
genom
organ
similar
coronavirus
genom
predict
contain
function
open
read
frame
orf
marra
et
al
rota
et
al
thiel
et
al
sarscov
genom
express
start
translat
two
larg
replic
polyprotein
kda
kda
encod
viral
replicas
gene
nt
compris
orf
remain
twelv
orf
encod
four
structur
protein
n
e
eight
accessori
protein
thiel
et
al
ziebuhr
sarscov
drug
discoveri
requir
develop
reliabl
biolog
assay
tradit
antivir
assay
coronaviru
base
viral
infect
cultur
cell
follow
monitor
compound
inhibit
viral
replic
observ
cytopath
effect
quantif
viral
yield
plaqu
assay
measur
viral
rna
revers
transcriptionpcr
iven
et
al
wu
et
al
viru
infect
mani
cell
type
produc
plaqu
hofmann
howev
requir
infecti
viru
work
carri
biosafeti
level
condit
make
difficult
use
live
viru
assay
highthroughput
screen
ht
identifi
antivir
compound
lowthroughput
natur
assay
limit
use
screen
compound
librari
avail
revers
genet
system
mani
coronaviru
cdna
clone
infecti
fulllength
genom
subgenom
replicon
made
possibl
develop
novel
assay
ht
thiel
et
al
yount
et
al
yount
et
al
principl
report
gene
gfp
could
engin
fulllength
viru
subgenom
replicon
infect
transfect
suscept
cell
report
viru
replicon
result
express
gfp
level
gfp
fluoresc
would
reflect
extent
viral
replic
could
use
monitor
suppress
viral
infect
potenti
inhibitor
ge
et
al
hertzig
et
al
stabl
bhk
cell
line
replic
sarscov
replicon
express
green
fluoresc
protein
gfp
gene
coexpress
polyprotein
contain
select
marker
gene
blasticidinresist
gene
blar
recent
describ
ge
et
al
report
util
cell
line
format
highthroughput
screen
report
initi
success
use
assay
identifi
compound
antivir
activ
screen
librari
compound
screen
identifi
seven
small
molecul
reduc
gfp
fluoresc
well
sarscov
protein
rna
synthesi
sarscov
replicon
cell
efficaci
compound
sarscov
infect
vero
cell
also
measur
plaqu
reduct
assay
pra
addit
target
one
hit
compound
valid
gener
resist
replicon
cell
identif
mutat
confer
drugresist
phenotyp
chemic
librari
screen
repres
broad
wellbalanc
collect
compound
accumul
number
year
varieti
distinct
sourc
compound
provid
guangdong
institut
materia
medica
compound
dissolv
dimethyl
sulfoxid
dmso
mm
transfer
microtit
plate
assay
antivir
activ
final
compound
concentr
use
primari
screen
final
dmso
concentr
sarscov
replicon
cell
line
stabli
express
sarscov
replicon
encod
gfp
describ
previous
ge
et
al
cell
cultur
plate
dmem
medium
gibco
contain
fetal
calf
serum
gibco
gml
blasticidin
invitrogen
use
passag
ensur
reproduc
babi
hamster
kidney
bhk
african
green
monkey
kidney
cell
vero
cell
line
purchas
american
type
cultur
collect
atcc
maintain
dulbecco
modifi
eagl
medium
dmem
invitrogen
supplement
fetal
bovin
serum
fb
invitrogen
c
co
replicon
cell
plate
clearbottom
plate
corn
inc
corn
new
york
cellswel
dmem
plu
fb
gml
blasticidin
cultur
media
remov
incub
replac
fresh
medium
without
blasticidin
twentyfour
hour
later
compound
ad
final
concentr
dmso
use
biomek
nx
robot
liquid
handler
beckman
coulter
fullerton
ca
plate
seal
ga
permeabl
membran
incub
humidifi
incub
c
co
day
well
examin
gfp
express
use
argon
laserscan
microscop
carl
zeiss
oberkochen
germani
microscop
set
excit
nm
emiss
nm
fluoresc
imag
well
convert
signal
valu
cytotox
measur
primari
hit
compound
mtt
assay
use
plate
approxim
vero
cell
l
medium
seed
per
well
plate
h
incub
l
compound
dissolv
dmso
ad
cell
vari
concentr
h
incub
cell
reach
confluenc
l
mtt
reagent
ad
well
cell
incub
anoth
h
l
deterg
reagent
ad
well
plate
swirl
gentli
left
dark
room
temperatur
h
absorb
record
microtit
plate
reader
molecular
devic
corpor
sunnyval
ca
filter
flow
cytometri
analysi
use
determin
candid
compound
differ
concentr
compound
ad
monolay
cell
plate
untreat
well
serv
control
two
day
later
cell
analyz
beckman
coulter
epic
altra
flow
cytomet
four
duplic
test
perform
inhibit
report
gene
express
calcul
reduct
mean
fluoresc
intens
mfi
gfpposit
cell
set
mfi
untreat
cell
inhibit
complet
regul
gfp
background
level
inhibit
cell
scan
green
fluoresc
use
beckman
coulter
epic
altra
flow
cytomet
data
collect
analyz
use
winmdi
data
analysi
program
scripp
research
institut
result
express
valu
defin
concentr
compound
achiev
inhibit
replicon
fluoresc
signal
compar
untreat
control
cell
realtim
rtpcr
analys
perform
quantifi
copi
number
replicon
rna
cell
drug
treatment
primer
rtpcr
condit
use
previous
describ
ge
et
al
realtim
pcr
signal
analyz
use
lightcycl
softwar
roch
version
size
uniqu
pcr
product
verifi
perform
melt
curv
agaros
gel
electrophoresi
copi
number
replicon
rna
determin
direct
comparison
intern
standard
replicon
rna
express
level
express
number
copiesg
total
rna
datum
point
repres
averag
five
replic
cell
cultur
total
cell
lysat
harvest
replicon
cell
cell
sd
sampl
buffer
lysat
heat
c
min
presenc
dtt
electrophoresi
sdspage
gel
transfer
onto
polyvinyliden
difluorid
pvdf
membran
millipor
corpor
billerica
block
use
trisbuff
salin
tbst
buffer
contain
nonfat
milk
membran
next
hybrid
overnight
cold
room
use
pro
antibodi
kind
gift
dr
zhang
liang
guangzhou
medic
colleg
wash
three
time
ice
cold
tbst
incub
goat
antirabbit
horseradish
peroxidas
hrp
conjug
antibodi
promega
h
reaction
detect
use
chemiglow
chemiluminesc
reagent
alpha
innotech
san
leandra
ca
imag
spot
densitometri
perform
alpha
imag
alpha
innotech
control
blot
strip
reprob
antiactin
santa
cruz
biotechnolog
santa
cruz
ca
mab
detect
describ
sarscov
strain
kindli
provid
chines
nation
institut
viral
diseas
control
prevent
degre
protect
offer
test
compound
sarscov
infect
measur
plaqu
reduct
assay
briefli
one
hundr
plaqu
form
unit
pfu
sarscov
ad
individu
well
tissu
cultur
plate
seed
monolay
vero
cell
cell
per
well
dmem
fb
h
incub
inocula
remov
cell
wash
phosphatebuff
salin
solut
pb
one
millilitr
overlay
lowmelt
agaros
dmem
fb
either
lack
test
compound
differ
concentr
compound
ad
well
h
incub
c
co
cultur
medium
remov
cell
cultur
plate
fix
formalin
solut
stain
crystal
violet
solut
plaqu
number
count
inhibitori
concentr
defin
concentr
plaqu
number
reduc
half
cell
cultur
without
addit
antivir
drug
experi
perform
three
time
independ
drug
valu
calcul
averag
deviat
sd
three
experi
procedur
involv
manipul
live
sarscov
carri
biolog
safeti
level
contain
laboratori
evalu
gener
viral
resist
specif
inhibitor
replicon
cell
plate
sixwel
plate
densiti
cell
per
well
serial
pass
presenc
gml
blasticidin
inhibitor
fresh
media
compound
ad
monolay
everi
day
cell
split
whenev
reach
confluenc
compound
control
cell
littl
cell
death
observ
monolay
cell
maintain
throughout
cultur
cell
incub
blasticidin
inhibitor
cell
die
week
small
coloni
order
cell
start
appear
expand
anoth
week
analyz
presenc
specif
resist
mutat
sarscov
proteas
domain
statist
analysi
perform
use
twotail
student
ttest
p
consid
signific
data
express
mean
sd
triplic
sampl
reproduc
confirm
three
separ
experi
recent
describ
cell
line
stabli
express
sarscov
replicon
encod
gfp
report
gene
blasticidinresist
gene
fig
allow
viral
replic
monitor
simpli
measur
fluoresc
intens
cell
adapt
gfpexpress
replicon
cell
line
ht
assay
initi
determin
linear
rang
report
cell
seed
plate
select
appropri
cell
number
per
well
critic
cell
densiti
could
affect
replic
effici
replicon
analysi
inhibitor
requir
quantif
decreas
steadyst
level
replicon
rna
examin
effect
cell
densiti
cell
seed
densiti
rang
cellswel
fluoresc
signal
correl
close
cell
number
fig
abl
consist
produc
easili
measur
fluoresc
signal
densiti
cellswel
densiti
select
ht
assay
furthermor
densiti
cell
becom
overli
confluent
assay
condit
replicon
copi
number
might
advers
affect
pietschmann
et
al
next
examin
effect
cell
passag
fluoresc
intens
show
activ
stabl
least
passag
data
shown
ht
assay
perform
cell
within
passag
origin
frozen
stock
passag
coloni
select
impact
dmso
concentr
also
examin
result
reveal
cell
toler
dmso
slight
decreas
fluoresc
signal
dmso
use
data
shown
therefor
ht
assay
dmso
concentr
limit
experiment
condit
assay
window
gfp
fluoresc
signal
repliconbear
cell
divid
background
signal
cell
consist
rang
data
shown
result
suggest
repliconcontain
cell
line
could
use
ht
assay
screen
compound
ht
assay
singl
concentr
singl
cell
employ
reduct
fluoresc
signal
criterion
evalu
approxim
compound
identifi
hit
rate
elimin
fals
posit
andor
cytotox
compound
compound
reevalu
concentr
man
data
repres
averag
three
independ
experi
b
name
compound
correspond
catalog
number
compound
librari
c
concentr
compound
produc
decreas
gfp
fluoresc
highest
concentr
compound
use
determin
concentr
compound
produc
decreas
mtt
signal
compound
test
cytotox
test
cell
e
concentr
plaqu
number
decreas
half
cell
cultur
without
addit
antivir
drug
reduct
viral
titer
determin
plaqu
assay
vero
cell
describ
section
highest
concentr
compound
use
determin
f
concentr
compound
produc
decreas
mtt
signal
cytotox
analyz
vero
cell
ualli
duplic
plate
prepar
sidebysid
fluoresc
assay
toxic
determin
rule
toxic
compound
upon
complet
assay
compound
reduc
gfp
fluoresc
less
retest
compound
toxic
bhk
cell
result
preliminari
candid
compound
select
analysi
triag
attempt
quantifi
activ
remain
candid
compound
serial
dilut
compound
prepar
assay
cell
determin
fluoresc
readout
doserespons
curv
compound
yield
valu
tabl
variabl
result
triplic
fluoresc
well
low
aberr
result
evid
rang
drug
concentr
test
candid
compound
next
assess
secondari
assay
ascertain
inhibit
sarscov
replicon
firstli
demonstr
compound
inhibit
sarscov
replicon
rna
replic
util
realtim
pcr
analyz
sarscov
rna
level
cell
treat
candid
compound
fig
show
compar
untreat
control
replicon
rna
level
significantli
reduc
h
treatment
candid
compound
reduc
replicon
rna
level
dosedepend
manner
log
chang
replicon
rna
copi
number
calcul
assay
compound
reduc
copi
number
per
g
rna
approxim
log
log
respect
h
incub
compound
signific
cytotox
evalu
mttbase
cell
viabil
assay
observ
replicon
cell
concentr
compound
secondli
antisarscov
activ
compound
replicon
cell
also
examin
protein
level
use
western
blot
analysi
specif
antibodi
sarscov
first
confirm
use
western
blot
analysi
show
sarscov
protein
present
replicon
cell
parent
cell
fig
western
blot
analysi
shown
fig
total
cell
protein
prepar
sarscov
replicon
cell
treat
candid
compound
viral
protein
detect
pro
antibodi
blot
strip
probe
betaactin
show
equal
load
shown
fig
compound
minim
effect
betaactin
level
consist
mtt
data
show
compound
cytotox
concentr
use
western
blot
data
demonstr
test
compound
reduc
sarscov
protein
level
replicon
cell
h
drug
treatment
dose
depend
also
clearli
seen
sever
compound
eg
structur
shown
tabl
howev
compound
reduc
viral
protein
highest
concentr
use
exampl
includ
tabl
comparison
western
blot
data
data
determin
fac
assay
demonstr
reason
good
correl
fluoresc
reduct
viral
protein
reduct
data
indic
candid
compound
inhibit
sarscov
replicon
rna
replic
also
prevent
replicon
protein
synthesi
thirdli
compound
inhibit
sarscov
plaqu
format
vero
cell
concentrationdepend
manner
valu
tabl
demonstr
protect
effect
observ
inde
due
presenc
inhibitor
result
demonstr
compar
could
obtain
replicon
assay
system
authent
sarscov
infect
assay
furthermor
valu
candid
compound
vero
cell
determin
tabl
indic
compound
cytotox
effect
antivir
concentr
summari
result
present
clearli
demonstr
replicon
assay
use
ht
compound
librari
preliminari
candid
compound
one
compound
design
display
potent
inhibitori
activ
find
line
previou
report
kao
et
al
b
report
specif
sarscov
pro
inhibitor
dock
favor
activ
site
sarscov
pro
kao
et
al
valid
target
chemicalresist
replicon
cell
select
genet
mutat
confer
resist
phenotyp
identifi
briefli
sarscov
replicon
cell
plate
sixwel
plate
presenc
gml
blasticidin
small
coloni
cell
size
observ
day
total
larg
coloni
cell
per
coloni
recov
two
separ
well
day
cell
recov
presenc
antivir
agent
nucleotid
sequenc
sarscov
pro
cdna
determin
rna
extract
rtpcr
describ
previous
ge
et
al
two
resist
variat
identifi
substitut
ile
sinc
nucleotid
chang
encod
origin
replicon
cdna
like
acquir
repli
cation
cell
cultur
marker
mutat
relat
drug
resist
import
aspect
drug
screen
new
viral
diseas
choic
assay
system
goal
studi
explor
genet
system
develop
ht
assay
sarscov
drug
discoveri
report
describ
develop
use
sarscov
repliconbas
ht
screen
discoveri
compound
potenti
antivir
activ
librari
compound
assay
use
preliminari
screen
concentr
detect
antivir
activ
measur
level
gfp
fluoresc
encod
sarscov
replicon
preliminari
candid
compound
defin
abil
reduc
gfp
fluoresc
activ
preliminari
candid
valid
retest
demonstr
absenc
cytotox
would
also
reduc
gfp
fluoresc
repliconbear
cell
activ
set
hit
sarscov
replic
confirm
demonstr
compound
reduc
level
sarscov
rna
protein
repliconbear
cell
use
replicon
assay
identifi
compound
met
criteria
select
inhibit
sarscov
rna
andor
protein
accumul
compound
present
tabl
find
show
select
activ
sarscov
line
previou
report
kao
et
al
lai
et
al
wu
et
al
yang
et
al
previou
report
also
found
compound
activ
west
nile
viru
gu
et
al
remain
three
compound
chemic
attract
chemic
stabl
nonreact
easi
synthes
deriv
appear
well
suit
analysi
importantli
compound
inhibit
sarscov
viral
product
live
viru
infect
assay
compound
show
potenti
optim
potent
inhibitor
sarscov
merit
detail
character
regard
mechan
action
present
target
valid
gener
resist
replicon
cell
identif
mutat
confer
drugresist
phenotyp
mechan
action
remain
six
candid
compound
known
whether
compound
target
viral
protein
cellular
process
involv
sarscov
replic
clear
assess
aspect
vitro
establish
sarscov
pro
helicas
assay
investig
whether
compound
inhibit
enzymat
activ
time
attempt
develop
viru
resist
candid
order
find
whether
specif
viral
protein
target
action
given
errorpron
replic
viral
rnadepend
rna
polymeras
preexist
variant
resist
specif
antisarscov
drug
sarscov
pro
inhibitor
could
get
select
wildtyp
sarscov
therapi
demonstr
resist
variat
select
vitro
sarscov
pro
specif
inhibitor
therefor
despit
potent
antisarscov
activ
demonstr
replicon
cell
optim
therapi
could
still
involv
combin
antivir
agent
best
illustr
treatment
hiv
combin
three
drug
variou
mechan
absolut
necessari
continu
suppress
viral
replic
emerg
resist
futur
examin
whether
effect
combin
sever
drug
addit
synergist
also
go
investig
whether
incub
replicon
cell
combin
sever
drug
would
help
suppress
emerg
vitro
resist
variat
conclus
report
describ
robust
screen
system
identif
drug
candid
select
activ
sarscov
screen
system
meet
requir
success
highthroughput
assay
minim
manipul
assay
setup
low
sampl
volum
autom
detect
endpoint
system
offer
consider
benefit
first
round
screen
regard
select
specif
toxic
compound
result
improv
data
set
initi
screen
comparison
exist
assay
base
simpler
observ
plaqu
format
analysi
cpe
system
eas
handl
good
level
safeti
well
suit
drug
discoveri
sarscov
applic
emerg
highrisk
pathogen
virus
furthermor
compound
identifi
may
use
research
tool
dissect
molecular
mechan
sarscov
replic
viral
host
interact
